Copyright
©The Author(s) 2016.
World J Gastrointest Oncol. Jul 15, 2016; 8(7): 543-549
Published online Jul 15, 2016. doi: 10.4251/wjgo.v8.i7.543
Published online Jul 15, 2016. doi: 10.4251/wjgo.v8.i7.543
Table 4 Gastrointestinal recovery, complication and hospital stay
Patients with selective COX-2 inhibitor (n = 75) | Patients without selective COX-2 inhibitor (n = 75) | P-value | |
Time to tolerate solid diet (d) | 1 (1-2) | 2 (2-3) | < 0.0011 |
Time to defecate (d) | 2 (2-3) | 3 (3-4) | < 0.0011 |
Overall complication | 9 (11) | 17 (23) | 0.08 |
Grade I | 4 | 7 | |
Grade II | 5 | 7 | |
Grade III | 0 | 2 | |
Grade IV | 0 | 1 | |
Prolonged postoperative ileus | 4 (5) | 6 (8) | 0.75 |
Postoperative stay (d) | |||
Median (IQR) | 4 (3-5) | 5 (4-6) | < 0.0011 |
Mean (SD) | 4.3 (3.0) | 5.3 (2.5) | 0.0231 |
Readmission within 30 d | 3 (4) | 1 (1) | 0.62 |
- Citation: Lohsiriwat V. Opioid-sparing effect of selective cyclooxygenase-2 inhibitors on surgical outcomes after open colorectal surgery within an enhanced recovery after surgery protocol. World J Gastrointest Oncol 2016; 8(7): 543-549
- URL: https://www.wjgnet.com/1948-5204/full/v8/i7/543.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v8.i7.543